A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
This is a Phase II single center, open-label, single arm study in patients with advanced thymic epithelial tumors after failure of cisplatin-based combination chemotherapy. Patients will be treated with Pembrolizumab 200 mg every 3 weeks.
Thymic Epithelial Tumors
DRUG: Pembrolizumab
Response rate by RECIST 1.1, complete response plus partial response as determined by RECIST 1.1, 24 months
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, include safety profiles, 24 months|Progression free survival, time from the on-study date to date of disease progression, 24 months|Overall survival, time from the on-study date to death as a result of any cause, 24 months
This is a Phase II single center, open-label, single arm study in patients with advanced thymic epithelial tumors after failure of cisplatin-based combination chemotherapy. Patients will be treated with Pembrolizumab 200 mg every 3 weeks.